Why is "Chronic myelogenous leukemia" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-29 08:02:59
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is a clonal bone marrow stem cell disorder in which a proliferation of mature granulocytes and their precursors is found; characteristic increase in basophils is clinically relevant. It is a type of myeloproliferative neoplasm associated with a characteristic chromosomal translocation called the Philadelphia chromosome.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
The Evolution of Tyrosine Kinase Inhibitor Therapy: Improving Outcomes in Patients with Newly Diagnosed Chronic Myelogenous Leukemia - Journal of Hematology Oncology Pharmacy
-
Expression profiles of miR-411 and SPRY4 as indicators of disease progression and treatment in chronic myelogenous leukemia - Nature
-
Education Session Tackles Important Questions Relevant to the Changing Face of CML - ashpublications.org
-
Inside the Discovery That Changed CML Treatment Forever: Jorge Cortes, MD - AJMC
-
NBA Legend Kareem Abdul-Jabbar, 78, Was Terrified of His Chronic Myelogenous Leukemia (CML) Diagnosis— How He's Effectively Managing The Disease - SurvivorNet
-
Chronic Myeloid Leukemia (CML): Background, Pathophysiology, Epidemiology - Medscape
-
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia - The New England Journal of Medicine
-
Chronic Myelogenous Leukemia - CancerNetwork
-
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy - Haematologica
-
Understanding Chronic Myelogenous Leukemia (CML) - Moffitt
-
Chronic Myelogenous Leukemia (CML): Julio's Story - BMT infonet.org
-
Prospect of shorter treatment and cure for chronic myelogenous leukemia - Harvard Gazette
-
Alembic cancer generic secures tentative approval in US - ETPharma.com
-
FDA Approves Dasatinib for Some Children with CML - National Cancer Institute (.gov)
-
Chronic Myelogenous Leukemia (CML): 5 Things to Know - Medscape
-
Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis - Nature
-
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia - The New England Journal of Medicine
-
Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia - Nature
-
Chronic myelogenous leukemia: mechanisms underlying disease progression - Nature
-
CDK8/19 inhibition attenuates G1 arrest induced by BCR-ABL antagonists and accelerates death of chronic myelogenous leukemia cells - Nature
-
Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia - Nature
-
Cytogenetics of Fibroblastic Colonies in Ph-positive Chronic Myelogenous Leukemia - ScienceDirect.com
-
Nilotinib Can Be Discontinued in Some Patients with Chronic Myelogenous Leukemia - National Cancer Institute (.gov)
-
Sipa1 deficiency unleashes a host-immune mechanism eradicating chronic myelogenous leukemia-initiating cells - Nature
-
Asciminib a new player in treatment of TKI-resistant/intolerant chronic phase chronic myelogenous leukemia - Via Medica Journals
-
Chronic Myelogenous Leukemia Prognosis - news-medical.net
-
FDA Approves Bosutinib for Pediatric Chronic Myelogenous Leukemia - CancerNetwork
-
Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia - Haematologica
-
Chronic myelogenous leukemia presenting with Morel Lavallée lesion: A case report of a rare presentation - Wiley Online Library
-
NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice - Nature
-
New Path for Preventing Chronic Myelogenous Leukemia Relapse Discovered - Genetic Engineering and Biotechnology News
-
Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia - acsjournals.onlinelibrary.wiley.com
-
Management of chronic myelogenous leukemia with COVID-19 and hepatitis B - Frontiers
-
Chronic Myelogenous Leukemia Classification - news-medical.net
-
Bowel Perforation Secondary to Ponatinib Treatment in a Chronic Myelogenous Leukemia Patient: A Case Report - Cureus
-
Stopping TKI Treatment Is Safe, Improves Quality of Life for Some with CML - National Cancer Institute (.gov)
-
Selecting Treatment for Newly Diagnosed CML - Oncology News Central
-
Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia - Frontiers
-
Bilateral intracochlear hemorrhage: A rare onset of chronic myelogenous leukemia - Wiley Online Library
-
Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib | Blood Cancer Journal - Nature
-
Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia - The New England Journal of Medicine
-
Translocation tracker: digital droplet PCR in chronic myelogenous leukemia - Fred Hutchinson Cancer Center
-
Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia - Frontiers
-
Imatinib-Induced Bone Marrow Aplasia in Chronic Myelogenous Leukemia - Cureus
-
Pericardial Effusion Secondary to Nilotinib in an Elderly Patient With Chronic Myelogenous Leukemia - Cureus
-
BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia - The New England Journal of Medicine
-
Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib - Nature
-
Resveratrol induces apoptosis of human chronic myelogenous leukemia cells in vitro through p38 and JNK-regulated H2AX phosphorylation - Nature
-
A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib - Wiley Online Library
-
Proteinuria Higher With Dasatinib Exposure in Chronic Myelogenous Leukemia - Physician's Weekly
-
Gata2 -L359V impairs primitive and definitive hematopoiesis and blocks cell differentiation in murine chronic myelogenous leukemia model - Nature
-
Cancer - National Institutes of Health (.gov)
-
FDA Approves Nilotinib Formulation (Danziten) for Chronic Myeloid Leukemia - Oncology News Central
-
Complete Molecular Remission in Chronic Myelogenous Leukemia after Imatinib Therapy - The New England Journal of Medicine
-
Detection and quantification of residual disease in chronic myelogenous leukemia - Nature
-
How Gleevec Transformed Leukemia Treatment - National Cancer Institute (.gov)
-
Chronic Myelogenous Leukemia with Gastric Infiltration — Report of a Case Simulating Carcinoma of the Stomach - The New England Journal of Medicine
-
BCR-ABL %IS Kit Monitors CML Treatment Response - Clinical Lab Products
-
BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia - Nature
-
Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR–ABL tyrosine kinase - Nature
-
Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia - The New England Journal of Medicine
-
FDA Grants Accelerated Approval to Asciminib (Scemblix) for Chronic Myeloid Leukemia - Oncology News Central
-
Antibody eradicates leukemia stem cells - Newsroom | UCLA
-
AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects - Nature
-
Spontaneous Remission in a Patient with Chronic Myelogenous Leukemia - The New England Journal of Medicine
-
Imatinib induces H2AX phosphorylation and apoptosis in chronic myelogenous leukemia cells in vitro via caspase-3/Mst1 pathway - Nature
-
Chronic Myelogenous Leukemia — New Concepts - The New England Journal of Medicine
-
Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro - Nature
-
Chronic myelogenous leukemia molecular signature - Nature
-
Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells - Nature
-
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib - Nature
-
Cord-Blood Transplantation from an Unrelated Donor in an Adult with Chronic Myelogenous Leukemia - The New England Journal of Medicine
-
Novel structural co-expression analysis linking the NPM1 -associated ribosomal biogenesis network to chronic myelogenous leukemia - Nature
-
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia - JCI.org
-
How do harmful chronic myelogenous leukemia stem cells obtain their nutrients? - Medical Xpress
-
How do harmful chronic myelogenous leukemia stem cells obtain their nutrients? - EurekAlert!
-
FDA Approves Bosutinib for Some Pediatric Patients With CML - Oncology News Central
-
The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model - Nature
-
Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy - Nature
-
Bosulif Approved for Previously Treated Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia - Medical Professionals Reference
-
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia - acsjournals.onlinelibrary.wiley.com
-
The biology of chronic myelogenous leukemia:mouse models and cell adhesion - Nature
-
Surprising Results Change Treatment Approach in CML - Oncology News Central
-
Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia - Nature
-
NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib - Nature
-
P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate - Nature
-
FDA Approves New Imatinib (Imkeldi) Formulation for Various Cancer Types - Oncology News Central
-
Chronic Myelogenous Leukemia (CML): Amanda's Story - BMT infonet.org
-
Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells | Cell Research - Nature
-
A Pilot Study of Isotretinoin in the Treatment of Juvenile Chronic Myelogenous Leukemia - The New England Journal of Medicine
-
Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients - Nature
-
From Fertility Preservation to Testing Frequency: Current Key Concerns in CML - Oncology News Central
-
Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate - Nature
-
Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia – potential clinical significance - Nature
-
Planned pregnancy pregnancy in patient with chronic myelogenous leukemia treated with imatinib - Via Medica Journals
-
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α /ara-C - Nature
-
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi( ϕ )-LMC GROUP) - Nature
-
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy - acsjournals.onlinelibrary.wiley.com
-
Airman beats leukemia into remission - moody.af.mil
-
FDA Approval of Bosulif Adds to Toolkit of Treatment Options for Children With CML - Cure Today
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.